Effects of Campomanesia xanthocarpa on inflammatory processes, oxidative stress, endothelial dysfunction and lipid biomarkers in hypercholesterolemic individuals

Atherosclerosis

Volumn 234, Issue 1, 2014, Pages 85-92

  Viecili, Paulo Ricardo Nazário ^a,b   Borges, Diego Olschowsky ^b,c   Kirsten, Karina ^b   Malheiros, Jênifer ^b   Viecili, Eduardo ^b   Melo, Rodolfo Dahlem ^b   Trevisan, Gabriela ^d   da Silva, Mariane Arnoldi ^d   Bochi, Guilherme Vargas ^d   Moresco, Rafael Noal ^d   Klafke, Jonatas Zeni ^a,b  

^a UNIVERSIDADE DE CRUZ ALTA   (Brazil)

^b Instituto de Cardiologia de Cruz Alta   (Brazil)

^c UNIVERSIDADE FEDERAL DE CIÊNCIAS DA SAÚDE DE PORTO ALEGRE   (Brazil)

^d FEDERAL UNIVERSITY OF SANTA MARIA   (Brazil)

Author keywords

Advanced oxidation protein products; C reactive protein; Hypercholesterolemia; Ischemia modified albumin; Medicinal plant; Myrtaceae

Indexed keywords

ADVANCED OXIDATION PROTEIN PRODUCT; ALANINE AMINOTRANSFERASE; ASPARTATE AMINOTRANSFERASE; C REACTIVE PROTEIN; CAMPOMANESIA XANTHOCARPA EXTRACT; CREATININE; HIGH DENSITY LIPOPROTEIN; HYPOCHOLESTEROLEMIC AGENT; LIPID; LOW DENSITY LIPOPROTEIN; PLANT EXTRACT; TRIACYLGLYCEROL; UNCLASSIFIED DRUG; UREA; VERY LOW DENSITY LIPOPROTEIN; BIOLOGICAL MARKER; CHOLESTEROL;

ADULT; ANTIINFLAMMATORY ACTIVITY; ANTIOXIDANT ACTIVITY; ARTICLE; BLOOD SAMPLING; CAMPOMANESIA XANTHOCARPA; CHOLESTEROL BLOOD LEVEL; CONTROLLED STUDY; DIABETES MELLITUS; ENDOTHELIAL DYSFUNCTION; ENDOTHELIUM; FEMALE; HUMAN; HYPERCHOLESTEROLEMIA; HYPERTENSION; KIDNEY FUNCTION; LIVER FUNCTION; MAJOR CLINICAL STUDY; MALE; MYRTACEAE; OBESITY; OXIDATIVE STRESS; PLEIOTROPY; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; BLOOD; DOUBLE BLIND PROCEDURE; DRUG EFFECTS; INFLAMMATION; MIDDLE AGED; PATHOPHYSIOLOGY; PHYTOTHERAPY; VASCULAR ENDOTHELIUM;

BIOLOGICAL MARKERS; CHOLESTEROL; DOUBLE-BLIND METHOD; ENDOTHELIUM, VASCULAR; FEMALE; HUMANS; HYPERCHOLESTEROLEMIA; INFLAMMATION; MALE; MIDDLE AGED; MYRTACEAE; OXIDATIVE STRESS; PHYTOTHERAPY; PLANT EXTRACTS; TRIGLYCERIDES;

EID: 84897944980     PISSN: 00219150     EISSN: 18791484     Source Type: Journal    
DOI: 10.1016/j.atherosclerosis.2014.02.010     Document Type: Article

References (64)

1. Alice C.B., Siqueira N.C.S., Mentz L.A., Brasil Silva G.A.A., José K.F.D. Plantas Medicinais De Uso Popular: Atlas Farmacognóstico 1995, Ulbra, Canoas, Brazil.
2. Armstrong E.J., Morrow D.A., Sabatine M.S. Inflammatory biomarkers in acute coronary syndromes: part I: introduction and cytokines. Circulation 2006, 11:372-375.
3. Aronow W.S. Treatment of high-risk older persons with lipid-lowering drug therapy. Am J Ther 2008, 15:102-107.
4. Austin M.A., Rodriguez B.L., McKnight B., et al. Low-density lipoprotein particle size, triglycerides, and highdensity lipoprotein cholesterol as risk factors for coronary heart disease in older Japanese-American men. Am J Cardiol 2000, 86:412-416.
5. Bar-Or D., Lau E., Winkler J.V. Anovel assay for cobalt-albumin binding and its potential as a marker for myocardial ischemia: a preliminary report. JEmerg Med 2000, 19:311-315.
6. Bermudez E.A., Rifai N., Buring J., Manson J.E., Ridker P.M. Interrelationships among circulating interleukin-6, Creactive protein, and traditional cardiovascular risk factors in women. Arterioscler Thrombosis Vasc Biol 2002, 22:1668-1673.
7. Bhatt D.L., Steg P.G., OHhman G.M., et al. International prevalence, recognition, and treatment of cardiovascular risk factors in outpatients with atherothrombosis. JAm Med Assoc 2006, 295:180-189.
8. Braun T.M., Kang S., Taylor J.M. Aphase I/II trial design when response is unobserved in subjects with dose-limiting toxicity. Stat Methods Med Res 2012, [Epub ahead of print].
9. Davidson M.H. Ezetimibe: a novel option for lowering cholesterol. Expert Rev Cardiovasc Ther 2003, 1:11-21.
10. De Lorgeril M., Salen P., Martin J., Monjaud I., Delaye J., Mamelle N. Mediterranean diet, traditional risk factors, and the rate of cardiovascular complications after myocardial infarction. Circulation 1999, 99:779-785.
11. Descamps-Latscha B., Witko-Sarsat V., Nguyen-Khoa T., et al. Advanced oxidation protein products as risk factors for atherosclerotic cardiovascular events in nondiabetic predialysis patients. Am J Kidney Dis 2005, 45:39-47.
12. Devaraj S., Xu D.Y., Jialal I. C-reactive protein increases plasminogen activator inhibitor-1 expression and activity in human aortic endothelial cells: implications for the metabolic syndrome and atherothrombosis. Circulation 2003, 107:398-404.
13. Dickel M.L., Rates S.M., Ritter M.R. Plantas popularly used for loosing weight purposes in Porto Alegre, South Brazil. JEthnopharmacol 2007, 109:60-71.
14. Dinarello C.A. Anti-inflammatory agents: present and future. Cell 2010, 140:935-950.
15. Duarte M.M., Rocha J.B., Moresco R.N., et al. Association between ischemia-modified albumin, lipids and inflammation biomarkers in patients with hypercholesterolemia. Clin Biochem 2009, 42:666-671.
16. Fang S.Y., Roan J.N., Luo C.Y., Tsai Y.C., Lam C.F. Pleiotropic vascular protective effects of statins in perioperative medicine. Acta Anaesthesiol Taiwan 2013, 51:120-126.
17. Fischetti F., Carretta R., Borotto G., et al. Fluvastatin treatment inhibits leucocyte adhesion and extravasation in models of complement-mediated acute inflammation. Clin Exp Immunol 2004, 135:186-193.
18. Friedwald W.T., Levy R.I., Fredrickson D.S. Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without the use of preparative ultracentrifuge. Clin Chem 1972, 18:100-107.
19. Golomb B.A., Evans M.A.M. Statin adverse effects: a review of the literature and evidence for a mitochondrial mechanism. Am J Cardiovasc Drugs 2008, 8:373-418.
20. Gottlieb M.G.V., Da Cruz I.B.M., Duarte M.M.F., et al. Associations among metabolic syndrome, ischemia, infl{ligature}ammatory, oxidatives, and lipids biomarkers. JClin Endocrinol Metab 2010, 95:586-591.
21. Hamasaki S., Higano S.T., Suwaidi J.A., et al. Cholesterol-lowering treatment is associated with improvement in coronary vascular remodeling and endothelial function in patients with normal or mildly diseased coronary arteries. Arterioscler Thromb Vasc Biol 2000, 20:737-743.
22. Harrison D.G. Endothelial control of vasomotion and nitric oxide production: a potential target for risk factor management. Clin Cardiol 1996, 14:1-15.
23. Harrison D.G. Cellular and molecular mechanisms of endothelial cell dysfunction. JClin Invest 1997, 100:2153-2157.
24. Huddy K., Dhesi P., Thompson P.D. Do the frequencies of adverse events increase, decrease, or stay the same with long-term use of statins?. Curr Atheroscler Rep 2013, 15:301-305.
25. Jones P.H., Davidson M.H., Stein E.A., et al. Comparison of the efficacy and safety of rosuvastatin versus atorvastatina, sinvastatina and pravastatina across doses. Stellar study group. Am J Cardiol 2003, 92:152-160.
26. Lorenzi H. Árvores Brasileiras: Manual de Identificação e Cultivo de Plantas Arbóreas do Brasil 1992, Instituto Plantarum de Estudos da Flora, São Paulo.
27. Kaefer M., Piva S.J., De Carvalho J.A., et al. Association between ischemia modified albumin, inflammation and hyperglycemia in type 2 diabetes mellitus. Clin Biochem 2010, 43:450-454.
28. Kasap S., Gönenç A., Şener D.E., Hisar I. Serumcardiacmarkers in patients with acute myocardial infarction: oxidative stress, C-reactive protein and N-terminal probrain natriuretic peptide. JClin Biochem Nutr 2007, 41:50-57.
29. Klafke J.Z., Da Silva M.A., Panigas T.F., et al. Effects of Campomanesia xanthocarpa on biochemical, hematological and oxidative stress parameters in hypercholesterolemic patients. JEthnopharmacol 2010, 127:299-305.
30. Klafke J.Z., Da Silva M.A., Rossato M.F., et al. Antiplatelet, antithrombotic, fibrinolytic activities of Campomanesia xanthocarpa. Evid Based Complement Altern Med 2012, 2012:1-8.
31. Kleemann R., Kooistra T. HMG-CoA reductase inhibitors: effects on chronic subacute inflammation and onset of atherosclerosis induced by dietary cholesterol. Curr Drugs Targets Cardiovasc Haematol Disord 2005, 5:441-453.
32. Kotur-Stevuljevic J., Memon L., Stefanovic A., et al. Correlation of oxidative stress parameters and infl{ligature}ammatory markers in coronary arterydisease patients. Clin Biochem 2007, 40:181-187.
33. Krzystek-Korpacka M., Patryn E., Boehm D., Berdowska I., Zielinski B., Noczynska A. Advanced oxidation protein products (AOPPs) in juvenile overweight and obesity prior to and following weight reduction. Clin Biochem 2008, 41:943-949.
34. Li L., Roumeliotis N., Sawamura T., Renier G. C-reactive protein enhances LOX-1 expression in human aortic endothelial cells: relevance of LOX-1 to C-reactive protein-induced endothelial dysfunction. Circ Res 2004, 95:877-883.
35. Madamanchi N.R., Vendrov A., Runge M.S. Oxidative stress and vascular disease. Arterioscler Thromb Vasc Biol 2005, 25:29-38.
36. Mancini G.B., Tashakkor A.Y., Baker S., et al. Diagnosis, prevention, and management of statin adverse effects and intolerance: canadian working group consensus update. Can J Cardiol 2013, 29:1553-1568.
37. Marino M., Pallottini V., D'Eramo C., Cavallini G., Bergamini E., Treantalance A. Age-related changes of cholesterol and dolichol biosynthesis in rat. Mech Ageing Dev 2002, 123:1183-1189.
38. Markman B.E., Bacchi E.M., Kato E.T. Antiulcerogenic effects of Campomanesia xanthocarpa. JEthnopharmacol 2004, 94:55-57.
39. Marsche G., Frank S., Hrzenjak A., et al. Plasma-advanced oxidation protein products are potent high-density lipoprotein receptor antagonists invivo. Circ Res 2009, 104:750-757.
40. Nedeljkovic Z.D., Gokce N., Loscalzo J. Mechanisms of oxidative stress and vascular dysfunction. Postgrad Med J 2003, 79:195-200.
41. National Cholesterol Education Program Executive summary of the third report. Expert panel on detection, evaluation, and treatment of high blood cholesterol in adults (Adults Treatment Panel III). JAm Med Assoc 2001, 285:2486-2497.
42. Packard R.R.S., Libby P. Inflammation in atherosclerosis: from vascular biology to biomarker discovery and risk prediction. Clin Chem 2008, 54:24-38.
43. Pallottini V., Martini C., Cavallini G., et al. Age-related HMG-CoA reductase deregulation depends on ROS-induced p38 activation. Mech Ageing Dev 2007, 128:688-695.
44. Pallottini V., Martini C., Pascolini A., et al. 3-Hydroxy-3-methylglutaryl coenzyme A reductase deregulation and age-related hypercholesterolemia: a new role for ROS. Mech Ageing Dev 2005, 126:845-851.
45. Patrick J.E., Kosoglou T., Stauber K.L., et al. Disposition of the selective cholesterol absorption inhibitor ezetimibe in healthy male subjects. Drug Metab Dispos 2002, 30:430-437.
46. Postadzhiyan A.S., Tzontcheva A.V., Kehayov I., Finkov B. Circulating soluble adhesion molecules ICAM-1 and VCAM-1 and their association with clinical outcome, troponin T and C-reactive protein in patients with acute coronary syndromes. Clin Biochem 2008, 41:126-133.
47. Rao A.V., Gurfinkel D.M. The bioactivity of saponins: triterpenoid and steroidal glycosides. Drug Metab Dispos 2000, 17:211-235.
48. Redón J., Oliva M.R., Tormos C., et al. Antioxidant activities and oxidative stress byproducts in human hypertension. Hypertension 2003, 41:1096-1101.
49. Ridker P.M., Hennekens C.H., Buring J.E., Rifai N. C-reactive protein and other markers of inflammation in the prediction of cardiovascular disease in women. NEngl J Med 2000, 342:836-843.
50. Ridker P.M., Danielson E., Fonseca F.A., et al. Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein. NEngl J Med 2008, 359:2195-2207. JUPITER Study Group.
51. Sakamotok K., Yamamoto Y., Okamatsu H., Okabe M. D-dimer is helpful for differentiating acute aortic dissection and acute pulmonary embolism from acute myocardial infarction. Hellenic J Cardiol 2011, 52:123-127.
52. Siekmeier R., Grammer T., März W. Roles of oxidants, nitric oxide, and asymmetric dimethylarginine in endothelial function. JCardiovasc Pharmacol Ther 2008, 13:279-297.
53. Silva Pereira R., Tatsch E., Bochi G.V., et al. Assessment of oxidative, inflammatory, and fibrinolytic biomarkers and DNA strand breakage in hypercholesterolemia. Inflammation 2013, 36:869-877.
54. Sparg S.G., Light M.E., Van Staden J. Biological activities and distribution of plant saponins. JEthnopharmacol 2004, 94:219-243.
55. Stadtman E.R. Protein oxidation and aging. Science 1992, 257:1220-1224.
56. Stadtman E.R., Levine R.L. Free radical-mediated oxidation of free amino acids and amino acid residues in proteins. Amino Acids 2003, 25:207-218.
57. Stamler J., Wentworth D., Neaton J.D. Is relationship between serum cholesterol and risk of premature death from coronary heart disease continuous and graded?. JAm Med Assoc 1986, 256:2823-2828.
58. Tatsch E., Bochi G.V., Pereira R.S., Kober H., Oliveira J.R., Moresco R.N. Asimple and inexpensive automated technique for measurement of serum nitrite/nitrate. Clin Biochem 2011, 44:348-350.
59. Tavridou A., Efthimiadis A., Efthimiadis I., Paschalidou H. Antioxidant effects of simvastatin in primary and secondary prevention of coronary heart disease. Eur J Clin Pharmacol 2006, 62:485-489.
60. Tousoulis D., Kampoliam A.M., Tentolouris C., Papageorgiou N., Stefanadis C. The role of nitric oxide on endothelial function. Curr Vasc Pharmacol 2012, 10:4-18.
61. Vassalle C., Pratali L., Boni C., Mercuri A., Ndreu R. An oxidative stress score as a combined measure of the pro-oxidant and anti-oxidant counterparts in patients with coronary artery disease. Clin Biochem 2008, 41:1162-1167.
62. Venugopal S.K., Devaraj S., Yuhanna I., Shaul P., Jialal I. Demonstration that C-reactive protein decreases eNOS expression and bioactivity in human aortic endothelial cells. Circulation 2002, 106:1439-1441.
63. Witko-Sarsat V., Friedlander M., Nguyen Khoa T., et al. Advanced oxidation protein products as a novel mediators of inflammation and monocyte activation in a chronic renal failure. Open J Immunol 1998, 161:2524-2532.
64. Witko-Sarsat V., Friedlander M., Capeillère-Blandin C., et al. Advanced oxidation protein products as a novel marker of oxidative stress in uremia. Kidney Int 1996, 49:1304-1313.